Biotechnology Frontier June 2013, Volume 2, Issue 2, PP.12-19
Expression of Epitope Vaccine CTB-UA against Helicobacter Pylori in Transgenic Tomato Xiaokang Li1, Xinyang Li1, Xuanquan Wang1, Le Guo 2, Yingying Xing1,Tao Xi1# 1. School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China 2. School of Laboratory Medicine, Ningxia Medical University, Yinchuan, 750004, China #
Email: xiaokangli_cpu@126.com
Abstract Helicobacter pylori is a key reason for Stomach diseases, and how to eradicate Helicobacter pylori has been studied for several decades. Oral vaccines produced by transgenic plants would change the traditional means of production and inoculation of Helicobacter pylori vaccines and reduce the vaccination cost significantly. In this research for the first time we used the transgenic tomato system to express Helicobacter pylori epitope vaccine CTB-UA, a recombinant peptide which could protect BALB/c mice from Helicobacter pylori infection after oral immunization by increasing the specific antibodies. CTB-UA was transformed into tomato mediated by Agrobacterium tumifient EHA105, and transgenic shoots have been verified by PCR analysis, RT-PCR and Enzyme-linked immunosorbent assay (ELISA) analysis showed that CTB-UA gene could transcript and produce the target peptide in the roots, fruits and leaves from the three transgenic tomato lines. Transgenic tomato derived oral vaccine strategy could be potentially used as an alternative strategy to fight for the H. pylori infection, especially for the people in developing worlds. Keyswords: Helicobacter Pylori; CTB-UA; Transgenic Tomato; Plant Vaccine
1 INTRODUCTION Helicobacter pylori (H. pylori), a slow-growing microaerophilic bacterium, chronically infects gastric epithelial cell surfaces and the overlying mucin layer mediated by adhesins[1-2]. H. pylori is considered to be a pivotal factor in the development of human gastrointestinal tract diseases (e.g. chronic active gastritis, gastric and duodenal ulcers, gastric adenocarcinoma[3] and gastric mucosa-associated lymphoid tissue lymphoma[4]). Since spread from person to person through fecal-oral or oral-oral routes easily, persist for life on the stomach mucosal surface, and has a high rate of recurrence unless treatment is taken, H. pylori infects more than 50% of the world’s population[5-6]. In developing world the infection rate is more immense that can reach to 90% or more[7], and the infection presents a nosogeographic or household trends. Traditional treatments of H. pylori are antibiotics-based triple or quadruple therapies and other multidrug cocktails. Many studies on the efficacy of antibiotic therapy have reported poor results and eradication rates of standard triple therapy had fallen from originally >90% to 70%-80% in some areas[8]. Researchers found that immunifaction with H. pylori vaccine could not only prevent infection or reduce its intensity in a prophylactic setting, but also could act therapeutically to reduce the colonization levels in H. pylori infection. To date, various antigenic proteins or peptides identified from H. pylori and their modified products have been used in animal models, including Urease, VacA, CagA, FlaA, FlaB, catalase, lipoprotein, NAP, adhesion[9-10], etc. Thereafter, a few of these vaccines have been preformed on human beings[11]. Though vaccination has been considered to be an efficient and effective means to combat H. pylori and most of the information available for vaccine candidates can be obtained now. High price of vaccination makes it unaffordable for most people, especially in developing countries, because daily average income of nearly one billion people is less than us$1. In addition, the process of developing and manufacturing vaccines is #
CITATION-Xiaokang Li, Xinyang Li, Xuanquan Wang, et al. Expression of Epitope Vaccine CTB-UA against Helicobacter Pylori in Transgenic Tomato [J]. Ivy Publisher: Biotechnology Frontier, June 2013, Volume 2, Issue 2, PP.12-19 - 12 http://www.ivypub.org/bf